The three components of ColZen® act synergistically, forming an innovative dressing that controls the exudate (wound fluid), reduces inflammation and edema, microbial colonization and accelerates the healing process.
It has also the benefit of being used every 72 hours, which offers convenience for the patient.
MINIMIZE THE AMOUNT OF EXCHANGE;
FRAMES UP TO EASILY CONTOUR OF WOUNDS;
DECREASE COLORIZATION BACTERIAL;
OPTIMIZES HALF TO ONE GOOD HEALING;
ALLOWS THE EXCHANGE FOR HALF WET;
ColZen® provides convenience of treatment to the patient, as it must be replaced on average every 72 hours or when needed.
ColZen® in contact with the wound becomes a transparent gel absorbed by the wound, which reduces the pain at the time of replenishment and permits the placement in the humid environment.
ColZen® molds easily to the contours of the wound and should be applied over the total area of the wound, must cover its entire length, and may be cut when necessary.
It assists in bleeding control and it can be used in the treatment of infected wounds or wounds in which there is an increased risk of infection.
1- Hart J, Silcock D, Gunnigle S, Cullen B, Light ND, Watt PW: The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing. Int J Biochem Cell Biol 2002 (34): 1557-1570.
2- Monafo L. The use of topical cerium nitrate-silver sulfadiazine in major burn Injuries. 1983; Panminerva Medica - v. 25: 151-154.
3- Burkes S & McCleskey CS. The bacteriostatic activity of cerium, lanthanum, and thalium. J Bacteriology 1947. 54: 417-425.
4- Monafo WW, Tandon SN, Ayvazian VH, Tuchshmidt J, Skinner AM, Deitz F. Cerium nitrate: A new topical antiseptic for extensive burns. Surgery 1976; 80, p. 465-473.
5- Herberger K, Rustembach SJ, Grams L, Munter KC, Schafer E, Augustin M. Quality-of-care for leg ulcers in the metropolitan area of Hamburg – a communitybased study. J European Acad Dermatol 2012; 26: 495-502.
6- Frade MAC, Assis RVC, Coutinho-Netto J, Andrade TAM, Foss NT. Biomembrana vegetal na cicatrização de úlceras venosas crônicas. An Bras Dermatol 2012; 87 (1): 45-51.
7- Mendez MV, Raffeto JD, Phillips TJ, Menzonian JO, Park HY. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: A potential mechanism for senescence in venous ulcers. J Vasc Surg 1999; 30: 734-43.
8- Deveci et al: Effects of cerium nitrate bathing and prompt burn wound excision on Il-6 and TNFa Levels in Burned Rats. Burns 2000, 26:41-5.
Silvestre Labs® is a pharmaceutical company with 100% national capital, located in Biotechnology Park of Rio de Janeiro (BIO-RIO), with expertise in dermatological and cosmetic products.
Silvestre Labs is part of Axis Biotec Brasil Group. Led by professionals with over 20 years of experience, Axis Biotec´s mission is to translate scientific research into innovative products and services in the healthcare industry.
The vocation for innovation can be measured from the first product launched by Silvestre Labs®: DERMAZINE®, an antimicrobial broad-spectrum and healing agent, composed of silver sulfadiazine 1%, which molecular synthesis of the active substance was developed and manufactured by the company itself.
From the knowledge gained in the development process of DERMAZINE®, new products with healing, antimicrobial, antiviral and immunomodulatory properties have been developed and launched such as COLZEN®, GINODERMAZINE®, DERMACERIUM® and DERMACERIUM HS GEL.
To know more about Silvestre Labs and its products, please visit www.silvestrelabs.com.
Química e Farmacêutica
Av. Carlos Chagar Filho, 791
Cidade Universitária - Ilha do Fundão
Rio de Janeiro - RJ
Zip Code: 21.941-904
+55 (21) 2142-7777
Copyright © Silvestre Labs® | 2015. All rights reserved. Desenvolvido por Ramosdesign.